Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Stock Has Consensus Target Price of $18.00

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $17.80.

A number of analysts recently commented on EPRX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 12th. Stifel Nicolaus set a $25.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Thursday. Wedbush began coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $17.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th.

Institutional Trading of Eupraxia Pharmaceuticals

A number of institutional investors have recently bought and sold shares of EPRX. Affinity Asset Advisors LLC lifted its stake in shares of Eupraxia Pharmaceuticals by 429.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after purchasing an additional 1,289,005 shares during the period. Jupiter Topco LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the second quarter worth $6,851,000. Seven Fleet Capital Management LP acquired a new stake in shares of Eupraxia Pharmaceuticals during the first quarter worth $5,137,000. Redmile Group LLC bought a new stake in Eupraxia Pharmaceuticals in the first quarter valued at about $5,068,000. Finally, Rubric Capital Management LP bought a new stake in Eupraxia Pharmaceuticals in the first quarter valued at about $5,004,000.

Eupraxia Pharmaceuticals Stock Up 0.2%

Shares of EPRX opened at $8.16 on Tuesday. The business’s fifty day moving average price is $7.15 and its two-hundred day moving average price is $7.00. The firm has a market capitalization of $530.56 million, a price-to-earnings ratio of -8.00 and a beta of 1.07. Eupraxia Pharmaceuticals has a 52 week low of $5.25 and a 52 week high of $9.32. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. On average, analysts predict that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients’ exposure to medication throughout the body.

Eupraxia’s development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company’s lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.